JDRF - Juvenile Diabetes Research Foundation

A JDRF-funded clinical trial has shown that a drug used to treat certain types of cancer can protect beta cells, and therefore preserve insulin production, in people newly diagnosed with type 1 diabetes.

The trial, conducted in the US through the international Type 1 Diabetes TrialNet consortium and published in the New England Journal of Medicine, provides the first conclusive evidence that it is possible to target particular types of immune cells to reduce or prevent the onset of type 1 diabetes.

Read more...

Australian scientists prevent onset of type 1 diabetes by making immune cells tolerate insulin-producing cells.

JDRF-funded researchers Ms Eliana Mariño and Dr Shane Grey have demonstrated the cells of the human immune system can be manipulated to prevent type 1 diabetes.

The body’s immune cells, or white blood cells, include B cells and T cells. B cells make antibodies and present ‘antigens’ to T cells, allowing them to recognise and kill invaders.

Previous research by the authors has showed that groups of B cells migrate to the pancreas and pancreatic lymph nodes and tell T cells to kill the cells that produce insulin.

Read more...

Scientists believe they may have found a preventative therapy for type 1 diabetes that makes the body tolerate the insulin-producing cells that would normally be attacked and destroyed at disease onset.

PhD student Eliana Mariño and Dr Shane Grey, from the Garvan Institute of Medical Research in Sydney, have demonstrated how a particular molecule may be used to prevent type 1 diabetes in the future. Their findings are published online in the international journal Diabetes.

JDRF’s Research Development Manager said this research, part funded by JDRF, is significant. “These results are impressive and they represent a promising step towards a vaccine for type 1 diabetes.”

Read more...